<DOC>
	<DOCNO>NCT00132418</DOCNO>
	<brief_summary>The objective study evaluate safety Enbrel ( etanercept ) rheumatoid arthritis ( RA ) subject great equal 1 document comorbid disease ( diabetes mellitus ; chronic pulmonary disease ; pneumonia within last year ; recurrent bronchitis , sinusitis , urinary tract infection ) might increase infection risk .</brief_summary>
	<brief_title>Study Enbrel Rheumatoid Arthritis ( RA ) Subjects With Comorbid Disorders</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Active RA Documented comorbid condition ( diabetes mellitus require insulin oral hypoglycemic agent ; chronic pulmonary disease ; history pneumonia last year ; recurrent bronchitis , sinusitis urinary tract infection ) Able selfinject study drug Previous use antitumor necrosis factor ( TNF ) monoclonal antibody Receipt antiCD4 diphtheria interleukin2 fusion protein within previous 6 month subsequent abnormal absolute T cell count Receipt intraarticular corticosteroid within 2 week screen Receipt cyclosporine , thalidomide azathioprine within 4 week screen Significant concurrent medical disease ( serious infection ; open cutaneous ulcer ; current antibiotic treatment ; myocardial infarction [ MI ] within 12 month screen ; angina pectoris ; uncontrolled hypertension ; cancer ; HIV positive )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>rheumatoid arthritis least 1 qualify comorbid condition ( diabetes , chronic pulmonary disease , recent infection )</keyword>
	<keyword>RA</keyword>
	<keyword>rheumatoid arthritis</keyword>
</DOC>